Screening for chronic liver diseases in the general population
Non-invasive Screening for Chronic Liver Diseases in the General Population. A Prospective Study
This study is testing a new screening program to help find people at risk for serious liver problems using a blood test and a special scan to improve their care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 260 (estimated) |
| Ages | 40 Years and up |
| Sex | All |
| Sponsor | University Hospital, Montpellier Academic / other |
| Locations | 1 site (Montpellier) |
| Trial ID | NCT06366425 on ClinicalTrials.gov |
What this trial studies
This study aims to improve the care of patients with chronic liver diseases by implementing a screening program in primary care settings. It focuses on assessing liver fibrosis using a combination of a blood test (FIB-4 score) and a non-invasive procedure (Fibroscan). The goal is to identify individuals at risk for advanced liver fibrosis and raise awareness about chronic liver diseases among healthcare providers and the general public. By refining the screening process, the study seeks to enhance patient outcomes and facilitate appropriate care for those affected.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 40 and older who do not have known liver pathologies but possess at least one risk factor for chronic liver disease.
Not a fit: Patients who have had a Fibroscan in the last 12 months or those with known liver diseases will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to earlier detection and better management of chronic liver diseases, ultimately improving patient outcomes.
How similar studies have performed: Previous studies have shown success with similar non-invasive screening approaches for liver diseases, indicating the potential effectiveness of this methodology.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 40 years * Without known liver pathologies * Having at least one risk factor for chronic liver disease: risky consumption of alcoholic beverages according to the AUDIT questionnaire, the presence of metabolic syndrome, diabetes or a risk factor for viral hepatitis B, D or C. Exclusion Criteria: * Fibroscan already performed in the last 12 months * Failure to collect express oral consent * Patient not affiliated with or not benefiting from a national health insurance scheme * Patient protected by law * Patient under guardianship or curatorship * Patient deprived of liberty * Pregnant or breastfeeding woman
Where this trial is running
Montpellier
- CHU de Montpellier — Montpellier, France (Recruiting)
Study contacts
- Study coordinator: Magdalena MESZAROS, MD
- Email: m-meszaros@chu-montpellier.fr
- Phone: 04 67 33 02 57
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.